Vaxart (OTCMKTS:VXRT) Stock Passes Above 50-Day Moving Average - Time to Sell?

Key Points

• Technical breakout: Shares of Vaxart passed above its 50‑day moving average of $0.68, trading as high as $0.76 and last at $0.7399 on volume of 333,049, with the 200‑day moving average at $0.52.
• Strong quarterly beat: Vaxart reported $0.24 EPS vs. a consensus of ($0.08) and revenue of $104.24M vs. $35.95M expected, alongside a 33.83% ROE and a 6.88% net margin.
• Analyst and institutional interest: Wall Street Zen upgraded the stock to a "buy" and several hedge funds (Marshall Wace, Jones Financial, Goldman Sachs, Invesco) have added or increased positions, while institutional ownership stands near 18%.

Shares of Vaxart, Inc. (OTCMKTS:VXRT - Get Free Report) passed above its 50-day moving average during trading on Thursday . The stock has a 50-day moving average of $0.68 and traded as high as $0.76. Vaxart shares last traded at $0.7399, with a volume of 333,049 shares.

Wall Street Analyst Weigh In

Separately, Wall Street Zen upgraded Vaxart to a "buy" rating in a research note on Friday, January 23rd.

Vaxart Stock Up 0.2%

The firm has a market cap of $178.62 million, a P/E ratio of 12.33 and a beta of 1.31. The company has a fifty day simple moving average of $0.68 and a 200-day simple moving average of $0.52.

Vaxart (OTCMKTS:VXRT - Get Free Report) last released its quarterly earnings data on Thursday, March 12th. The biotechnology company reported $0.24 earnings per share for the quarter, topping analysts' consensus estimates of ($0.08) by $0.32. The firm had revenue of $104.24 million during the quarter, compared to analyst estimates of $35.95 million. Vaxart had a return on equity of 33.83% and a net margin of 6.88%.

Hedge Funds Weigh In On Vaxart

A number of hedge funds have recently made changes to their positions in VXRT. Marshall Wace LLP bought a new position in shares of Vaxart in the second quarter worth about $794,000. Jones Financial Companies Lllp boosted its stake in shares of Vaxart by 276,364.7% in the first quarter. Jones Financial Companies Lllp now owns 478,284 shares of the biotechnology company's stock worth $196,000 after acquiring an additional 478,111 shares during the period. Goldman Sachs Group Inc. bought a new position in shares of Vaxart in the first quarter worth about $31,000. Creative Planning bought a new position in shares of Vaxart in the second quarter worth about $33,000. Finally, Invesco Ltd. boosted its stake in shares of Vaxart by 93.1% in the first quarter. Invesco Ltd. now owns 146,366 shares of the biotechnology company's stock worth $60,000 after acquiring an additional 70,568 shares during the period. Institutional investors own 18.05% of the company's stock.

About Vaxart

Vaxart, Inc is a clinical-stage biotechnology company pioneering the development of oral recombinant vaccines administered in tablet form. Leveraging a proprietary, room-temperature-stable platform, the company aims to simplify vaccine delivery while eliciting both systemic and mucosal immune responses. Its technology is based on the replication-defective adenovirus vector system, which encodes target antigens designed to protect against a range of infectious diseases without the need for injections or cold-chain logistics.

The company’s pipeline includes multiple vaccine candidates in various stages of development.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.